Bristol-Myers Squibb Company (BMY)

BMY (NYSE:Drugs)
$47.00
pos +0.60
+1.29%
Today's Range: 45.87 - 47.22 | BMY Avg Daily Volume: 10,152,700
Last Update: 05/23/13 - 4:00 PM EDT
Volume: 11,885,800
YTD Performance: 35.19%
Open: $46.18
Previous Close: $46.40
52 Week Range: $30.64 - $47.48
Oustanding Shares: 1,642,551,939
Market Cap: 72,370,838,432
6-Month Chart
TheStreet Ratings Grade for BMY
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 6 6 6
Moderate Buy 1 1 1 1
Hold 12 13 13 12
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
Mean Rec. 2.45 2.48 2.48 2.45
Latest Dividend: 0.35
Latest Dividend Yield: 3.18%
Dividend Ex-Date: 04/03/13
Price Earnings Ratio: 49.51
Price Earnings Comparisons:
BMY Sector Avg. S&P 500
49.51 50.60 17.70
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
20.09% 41.85% 91.90%
GROWTH 12 Mo 3 Yr CAGR
Revenue -17.10 -0.06 -0.02
Net Income -52.50 -0.43 -0.17
EPS -46.30 -0.78 -0.39
Earnings for BMY:
EBITDA 4.77B
Revenue 17.62B
Average Earnings Estimates
Qtr (06/13) Qtr (09/13) FY (12/13) FY (12/14)
Average Estimate $0.45 $0.46 $1.81 $2.13
Number of Analysts 9 8 12 10
High Estimate $0.47 $0.48 $1.85 $2.42
Low Estimate $0.43 $0.44 $1.78 $1.93
Prior Year $0.48 $0.37 $1.99 $1.81
Growth Rate (Year over Year) -6.94% 24.32% -9.17% 17.73%
Update Chart
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
TripleDTrader
TripleDTrader: Lots of stocks now green on the day including, $DE $BA $AXP $MRK $BMY $AIG $CVX $MET $IP $TWX
2 hours ago from StockTwits Web
StockSignaling
StockSignaling: 25 Stocks To Watch: http://t.co/Vtx6dLy0Nw : $WETF $DHX $CBST $GILD $BMY $AMAT $NOC $STZ $BEAM $FANG $ALTR $AEO $URI $BMR $ABCO #investing
3 hours ago from Stock Signaling
Mutz_A
Mutz_A: Since when is $BMY a biotech company? Sure is trading like one. It has the high p/e part but not the earnings growth part. #bullmarket
3 hours ago from Twitter for iPhone
PickingBottoms
PickingBottoms: $BMY chart showing real strength- didn't even blink at the pullback these last couple days
4 hours ago from web
JPZaragoza1
JPZaragoza1: RT @chasingthealpha: Looks like I will be attending $NLNK and $BMY analyst events at ASCO, will keep @ChimeraResearch subs in the loop
4 hours ago from web
tony__teo
tony__teo: RT @chasingthealpha: Looks like I will be attending $NLNK and $BMY analyst events at ASCO, will keep @ChimeraResearch subs in the loop
5 hours ago from Twitter for iPhone
chasingthealpha
chasingthealpha: Looks like I will be attending $NLNK and $BMY analyst events at ASCO, will keep @ChimeraResearch subs in the loop
5 hours ago from TweetDeck
ColfaxCapital
ColfaxCapital: @chasingthealpha hopefully $BMY is next
5 hours ago from TweetDeck
brentpepper
brentpepper: RT @SeekingAlpha: Shades Of 1999 http://t.co/0KNjNkQbGu $AAPL $BMY $PBR $BP $CAT $CCL $CHK $COP $CRM $DNKN $GPS $KSS $M $PFE $SHLD $SXL $TIVO
6 hours ago from Twitter for iPhone
GantosJ
GantosJ: Finally have internet connection, see that I missed the $BMY fun, happy that we @ CRG picked those Jan $49 calls, paied back my vacation :))
6 hours ago from web

updateCredit Suisse Healthcare Conf.

Nov 14, 2012 | 6:42 AM EST

Credit Suisse Group AG Healthcare Conference

bearishBristol-Myers Squibb downgraded at BMO

Nov 12, 2012 | 8:14 AM EST

BMY was downgraded to Market Perform from Outperform, BMO said. $37 price target. A number of pipeline setbacks this year. 

Best Value Plays

By

Doug Kass

 | Nov 9, 2012 | 12:19 PM EST
Here is where I find the greatest value in certain sectors. 

Observations at Day's End

By

Doug Kass

 | Nov 5, 2012 | 4:15 PM EST
Here are some thoughts on stocks, the market and politics.

Levels

By

Doug Kass

 | Nov 5, 2012 | 9:55 AM EST
Currently, 13 out of the 71 stocks I have mentioned recently are eligible to buy, up from only three out of 70 two months ago.

Adding to Two Longs

By

Doug Kass

 | Nov 5, 2012 | 9:38 AM EST
Namely, CSX and Bristol-Myers.

Paring Back Longs

By

Doug Kass

 | Nov 1, 2012 | 10:25 AM EDT
Also, Oaktree just made another new high.

The Bristol-Myers Stomp

By

Doug Kass

 | Oct 31, 2012 | 2:18 PM EDT
Goin' to be buyin' some BMY. 

Thanks, Stephanie!

By

Doug Kass

 | Oct 25, 2012 | 10:32 AM EDT
Her input helped me to make an audible and buy back my Bristol-Myers position.

Returning to a Long on Bristol-Myers

By

Doug Kass

 | Oct 24, 2012 | 1:46 PM EDT
The quarter was not as bad as initially feared.

Columnist Conversation / Market Updates

Google Faces More Antitrst Probes
By

Doug Kass

 | May 23, 2013 | 4:00 PM EDT
Google faces new antitrust probe over display ad market

Market on Close Imbalance on the Sell Side
By

Doug Kass

 | May 23, 2013 | 3:47 PM EDT
There is about $550 million to sell on the close.
See more »

Our Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.